Media Inquiries

Meredith Kaya

Vice President, Investor Relations and Corporate Communications


Beth Calitri

Corporate Communications, Media Relations

Sort by Year
March 14, 2019

Ironwood Announces Effectiveness of Cyclerion Form 10 Registration Statement

March 7, 2019

Ironwood Pharmaceuticals to Present at Barclays Global Healthcare Conference

March 4, 2019

Ironwood Pharmaceuticals to Present at Cowen Health Care Conference

February 26, 2019

Cyclerion, the Planned R&D Spin-off of Ironwood Pharmaceuticals, Secures Commitments of $175 Million in Private Offering

February 21, 2019

Ironwood Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference

February 13, 2019

Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2018 Investor Update

January 28, 2019

Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2018 Investor Update Call

January 28, 2019

Ironwood Announces Filing of Form 10 Registration Statement in Connection with Planned Business Separation

January 15, 2019

Ironwood Pharmaceuticals Announces Approval of LINZESS® (linaclotide) in China for the Treatment of Adults with IBS-C

January 6, 2019

Ironwood Pharmaceuticals Appoints Michael Shetzline, M.D., Ph.D. as Chief Medical Officer

January 4, 2019

Ironwood Pharmaceuticals Announces Chief Executive Officers to Lead Ironwood and Cyclerion, Effective Upon Upcoming Separation

January 2, 2019

Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

January 2, 2019

Ironwood and Allergan Announce Settlement with Mylan Resolving LINZESS® (linaclotide) Patent Litigation

November 8, 2018

Ironwood Pharmaceuticals to Present at 27th Annual Credit Suisse Healthcare Conference

November 6, 2018

Ironwood Pharmaceuticals Provides Third Quarter 2018 Investor Update

Copyright © 2021, Ironwood Pharmaceuticals, Inc. All Rights Reserved

LINZESS®, CONSTELLA®, IRONWOOD® and their associated logos are trademarks of Ironwood Pharmaceuticals, Inc. Any other trademarks referred to herein are the property of their respective owners. All rights reserved.